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A decade (1982 to 1992) of pediatric cardiac 
transplantation and the impact of FK 506 
. . ImmunosuppreSSIon 
The decade from 1982 through 1992 witnessed tremendous growth in pediatric cardiac transplantation. 
At Children's Hospital of Pittsburgh 66 cardiac transplants were performed during this period (age 
range 7 hours to 18 years). The cause of cardiomyopathy was congenital (n = 30), cardiomyopathy 
(n = 29), myocarditis (n = 2), doxorubicin toxicity (n = 2), ischemic (n = 1), valvular (n = 1), and car-
diac angiosarcoma (n = 1). Nine children (14 %) required mechanical circulatory support before trans-
plantation: extracorporeal membrane oxygenation (n = 8) and Novacor left ventricular assist system 
(n = 1) (Baxter Healthcare Corp., Novacor Div., Oakland, Calif.). The mean foUow-up time was 2 
years (range 4 months to 8 years). The overaU survival in the group was 67%. In children with 
congenital heart disease (>6 months of age) the perioperative (30 day) mortality was 66% before 
mid-1988 (n = 10) and 0% since mid-1988 (n = 11). The late mortality (>30 days) in children with 
cardiomyopathy transplanted prior to mid-1988 was 66% (n = 14) and 7% since mid-1988 (n = 15). 
Since mid-1988 1- and 3-year survival was 82% in children with congenital heart disease and 90% in 
children with cardiomyopathy. Twenty-six children have had FK 506 as their primary immunosuppres-
sive therapy since November 1989. Survival in this group was 82 % at 1 and 3 years. The actuarial 
freedom from grade 3A rejection in the FK group was 60 % at 3 and 6 months after transplantation 
versus 20 % and 12 %, respectively, in the 15 children operated on before the advent of FK 506, who 
were treated with cyclosporioe-based triple-drug therapy (p < 0.001, Mantel-Cox and Breslow). Twen-
ty of 24 children (83 %) in the FK 506 group are receiving no steroids. The prevalence of posttrans-
plantation hypertension was 4 % in the FK 506 group versus 70 % in the cyclosporine group 
(p < 0.001, Fisher). Renal toxicity in children treated with FK 506 has been mild. AdditionaUy, eight 
children have been switched to FK 506 because of refractory rejection and drug toxicity. FK 506 has 
not produced hirsutism, gingival hyperplasia, or abnormal facial bone growth. The absence of these 
debilitating side effects, together with the observed immune advantage and steroid-sparing effects of FK 
506, hold tremendous promise for the young patient facing cardiac transplantation and a future 
wedded to immunosuppression. (J THORAC CARDIOVASC SURG 1993;105:464-73) 
John M. Armitage, MDa (by invitation), Frederick J. Fricker, MDb (by invitation), 
Pedro del Nido, MDa (by invitation), Thomas E. Starzl, MD, PhDa (by invitation), 
Robert L. Hardesty, MD,a and Bartley P. Griffith, MD,a Pittsburgh, Pa. 
From the Departments of Surgery" and Pediatrics,b University of Pitts-
burgh School of Medicine, Pittsburgh, Pa. 
Read at the Seventy-second Annual Meeting of The American Asso-
ciation for Thoracic Surgery, Los Angeles, Calif .. April 26-29, 1992. 
Address for reprints: John M. Armitage, MD, Department of Surgery, 
464 
University of Pittsburgh, School of Medicine, A I 0 I 0 Presbyterian-
University Hospital, DeSoto and O'Hara Sts., Pittsburgh, PA 
15213. 
Copyright © 1993 by Mosby-Year Book, Inc. 
0022-5223/93 $1.00 +.10 12/6/43206 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 105, Number 3 
The decade from 1982 to 1992 has witnessed tremendous 
growth in pediatric cardiac transplantation, The initial 
cautious application of heart transplantation in children 
has greatly expanded to include infants, children with 
complex congenital heart disease and multiple palliative 
procedures, as well as children at high risk because of 
pulmonary vascular disease and those requiring me-
chanical circulatory support, Children with cardiomyop-
athies of unusual cause such as cardiac tumor, doxorubi-
cin toxicity, Chagas' disease, carnitine deficiency, and 
myocarditis have benefited, as well, from transplantation, 
The technical challenges and infectious and immunolog-
ic risks, which are magnified in the pediatric heart recip-
ient, have been largely overcome, such that the child can 
now anticipate 80% to 90% survival at the first year after 
transplantation, Since our initial report on pediatric heart 
transplantation in 1988,1 perioperative and late mortali-
ty have declined dramatically, at a time when our candi-
date group has become increasingly high risk In addition, 
beginning in November 1989, the clinical trial ofFK 506 
immunosuppression for pediatric heart transplant recip-
ients was initiated at Children's Hospital of Pittsburgh. 
We report here our experience with this potent macrolide 
immunosuppressant, as well as our results in the 66 pedi-
atric cardiac transplant recipients during the past decade. 
Patients and methods 
Patient group. Sixty-six children, age range 7 hours to 18 
years, underwent cardiac transplantation from February 1982 
to April 1992, There were 40 boys and 26 girls, The causes of 
cardiomyopathy were congenital heart disease (n = 30) (Table 
I), cardiomyopathy (idiopathic, hypertrophic, and restrictive) 
(n = 29), myocarditis (n = 2), doxorubicin toxicity (n = 2), 
ischemic (n = I), valvular (n = I), and cardiac angiosarcoma 
(n = I). Nine patients (14%) required mechanical circulatory 
support before transplantation: Extracorporeal membrane oxy-
genation (ECMO) was used to support eight patients and a 
Novacor left ventricular assist system (L VAS) (Baxter Health-
care Corp., N ova cor Div" Oakland, Calif.) was used in one other 
patient. 14 years of age, The mean follow-up was 2 years (range 
4 months to 8 years), 
FK 506 patient group. Twenty-six children (age range 7 
hours to 18 years) have been enrolled in the study of FK 506 
immunosuppression after cardiac transplantation. There were 
16 boys and 10 girls, The causes of heart failure were cardio-
myopathy (n = 10) and congenital heart disease (n = 16) 
(Table I), Eleven patients (42%) were supported with mechan-
ical ventilation and/or inotropic agents before transplantation, 
Five patients (26%) required mechanical circulatory support: 
ECMO was used in four patients and a Novacor LV AS in one 
patient. All children with congenital heart disease in the FK 506 
group had prior cardiac or thoracic surgical procedures (aver-
age of 2,3 operations per patient), The mean follow-up time in 
the group was 405 days. 
Operation. Forty-five orthotopic cardiac transplants with 
moderate hypothermic cardiopulmonary bypass2 and one het-
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Table I. Types of congenital heart disease 
HLHS 
HLHS and T APVR 
HLHS and right interrupted aortic arch 
Single ventricle 
Tetralogy of Fallot 
Transposition of great arteries 
Tricuspid atresia 
Ventricular septal defect 
Coronary artery anomaly 
Aortic coarctation and LV OTO 
Total 
Cyclosporine 
and FK 506 FK 506 
8 
1 
I 
6 
3 
3 
3 
2 
2 
1 
30 
5 
1 
1 
4 
I 
1 
2 
HLHS, Hypoplastic left heart syndrome; TAPVR, total anomalous pulmonary 
venous return; LVOTO, left ventricular outflow tract obstruction. 
erotopic procedure3 were performed. Eight children with 
hypoplastic left heart syndrome (HLHS) required profound hy-
pothermia, circulatory arrest, and aortic reconstruction. Two 
children with HLHS had additional congenital cardiac repairs; 
one child had total anomalous pulmonary venous return and the 
other had an interrupted right-sided aortic arch. Ten children 
required pulmonary arterioplasty, end-to-end pulmonary arte-
rial anastomoses, end-to-end vena caval anastomoses, or a com-
bination of these, to reconstruct their anomalies. One of these 
children, with situs ambiguus and single ventricle, required 
inferior vena caval baffling as well. There were four second 
transplantations, 
Immunosuppression. All children, from 1982 until N ovem-
ber 1989, received cyclosporine-based immunosuppression. Ini-
tially, cyclosporine was used with steroids alone, then with tri-
ple-drug therapy (cyclosporine, azathioprine, and steroids), and 
fmally with rabbit antithymocyte globulin immunoprophylaxis 
and triple-drug therapy. Cyclosporine was begun during the 
postoperative period, enterally, 5 mg/kg per day, in two divided 
doses. The maintenance dose of cyclosporine varied from 4 to 20 
mg/kg per day to maintain a whole-blood radioimmunoassay 
cyclosporine level from 500 to 700 ng/ml or 150 to 250 mg/ml 
by high-performance liquid chromatography. Steroids and aza-
thioprine were begun before transplantation and continued after 
transplantation. On the basis of each child's rejection history, 
steroid weaning was begun at 6 to 12 months after transplan-
tation. 
Since November 1989, a prospective study with FK 506 and 
low-dose steroids was begun in children after hearftransplan-
tation, Informed consent was obtained from each family and 26 
children have now been treated with this agent Methylpred-
nisolone, 10 mg/kg, was administered intravenously in the 
operating room and 7 mg/kg per day in three divided doses 
during the first day after transplantation. Thereafter, pred-
nisone, 0.1 mg/kg per day, was given orally and discontinued 
after the first normal findings on endomyocardial biopsy. FK 
506 was begun in the intensive care unit after transplantation, 
0.05 mg/kg per day intravenously, as a continuous infusion, 
until gastrointestinal function returned, Oral FK 506, 0,3 
mg/kg per day in two divided doses, was begun 24 to 48 hours 
after transplantation, The oral dose of FK 506 to maintain a 
12-hour trough level of 0,2 to 0.8 ng/ml (serum enzyme-linked 
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Fig. 1. Survival in pediatric heart transplantation in children with cardiomyopathy, n = 29: 1982-1988, lower one-
sided Brookmeyer-Crowley 95% confidence limit for median survival time = 7.57 months; 1988-1992, Brookmeyer-
Crowley 95% confidence interval not calculable; all, lower one-sided Brookmeyer-Crowley 95% confidence limit for 
median survival time = 27.77 months. 
immunosorbent assay by the technique of Tamaura and col-
leagues3) has ranged from 0.2 to 0.4 mg/kg per day. 
Monitoring and treatment for rejection. Posttransplanta-
tion surveillance on all patients involved weekly transvenous 
endomyocardial biopsies during hospitalization and at slowly 
increased intervals after discharge. The neonatal patients under-
went biopsy at 1- to 3-month intervals. Biopsy specimens were 
graded by means of hematoxylin and eosin staining and light 
microscopy by a pathologist who was blinded to the immuno-
suppressive protocol of the patient. Biopsy grades were defined 
according to standardized nomenclature.4 Rejection was 
defined by the presence of myocyte necrosis in association with 
an interstitial lymphocytic infiltrate (grade 3A or 3B, moderate 
rejection) or with hemorrhage (grade 4, or severe rejection). 
Grade 3A or 3B rejection was treated with intravenous meth-
ylprednisolone, 5 mg/kg per day, for 3 days. Grade 4 rejection 
was treated with rabbit antithymocyte globulin or OKT3. 
Monitoring for infection and prophylaxis. All patients were 
followed up by a specialist in pediatric infectious disease. Pre-
transplantation titers for hepatitis A, B, C, and D, herpesvirus, 
Epstein-Barr virus, varicella, human immunodeficiency virus, 
Toxoplasma, and cytomegalovirus (CMV) were performed on 
all donors and recipients. If the date oftransplantation was more 
than I month after the initial visit, any serologic tests with neg-
ative results were repeated. An intermediate-strength tubercu-
lin skin test, along with an anergy panel, was also applied. 
Perioperative antibiotic coverage consisted of intravenous 
cefamandole and was maintained for 48 hours in recipients old-
er than 6 months of age. Neonatal recipients received ampicil-
lin and cefotaxime. Since 1989, our prophylactic strategy for 
CMV has included intravenous ganciclovir for 4 weeks, followed 
by acyclovir (650 mg/m2 per day) for 6 months. Only CMV-
negative blood products were administered. Oral mycostatin 
and trimethoprirn sulfamethoxazole were given to all patients 
after their transplant operation. Serologic follow-up for CMV, 
hepatitis, human immunodeficiency virus, Epstein-Barr virus, 
and toxoplasmosis was performed on all patients, both those who 
had seronegative studies at the time of transplantation and in 
seropositive patients to monitor for evidence of reactivation. 
Additionally, patients with fever episodes had cultures obtained 
from the blood, nasopharynx or throat, and urine for bacterial, 
fungal, and viral infection. More invasive procedures to obtain 
cultures were guided by the clinical presentation. The diagnosis 
of infection was made from clinical criteria as previously 
described.5,6 
Complete blood screening was performed daily in the hospi-
tal and at all follow-up visits. Questionnaires to identify unto-
ward side effects of FK 506 were completed on all patients. 
Results 
Survival and mortality 
Cardiomyopathy. In the 29 patients with idiopathic, 
hypertrophic, and dilated cardiomyopathy the survivals 
at 1 and 5 years were 74% and 63%, respectively. The 
perioperative «30 days) mortality for this group was 
1 0%. Fourteen patients with cardiomyopathy underwent 
transplantation from February 1982 to June 1988 (ear-
ly) and 15 patients with cardiomyopathy underwent 
transplantation from July 1988 to March 1992 (late). 
The perioperative mortality was 14% versus 6% in the 
early and late groups, respectively. However, the late 
mortality (> 30 days) was 66% in the early group and only 
7% in the late group. The major cause of late death in the 
early group (6/10) was rejection. The overall survival in 
the early group was 28% at 7 years and in the late group, 
87% at 4 years after transplantation (Fig. 1). 
Congenital heart disease. In the 21 patients with con-
genital heart disease who were 6 months and older, the 
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Fig. 2. Survival in pediatric heart transplantation in children with congenital heart disease (CHD). n = 21: 1982-
/988, lower one-sided Brookmeyer-Crowley 95% confidence limit for median survival time = 0.03 months; 
1988-1992, Brookmeyer-Crowley 95% confidence interval for median survival time is not calculable; all, lower one-
sided Brookmeyer-Crowley 95% confidence limit for median survival time = 2.90 months. 
survival at 1 and 5 years was 62%. The perioperative 
mortality was 35%. Ten patients underwent transplanta-
tion during the early period and 11 during the late peri-
od. The perioperative mortality was 60% in the early 
group and 0% in the late group. The major cause (5/6) 
of perioperative mortality was donor organ dysfunction 
and pulmonary vascular disease. The late mortality was 
0% versus 18% in the early and late groups, respectively. 
In the early group with congenital heart disease, 2 of 10 
children were supported by ECMO before transplanta-
tion and 8 of 10 children had an average of 1.1 prior car-
diac or thoracic operations. In the more recent group of 
children with congenital heart disease, 2 of 11 children 
were supported by ECMO before transplantation and 11 
of II children had an average of 2.3 prior cardiac or tho-
racic operations. The overall survival in the early group 
was 40% at 7 years and in the late group, 82% at 4 years 
after transplantation (Fig. 2). 
FK 506 immunosuppression. Twenty-six children 
were treated with FK 506 immunosuppression after car-
diac transplantation. The survival in the group was 82%. 
There were two early deaths «30 days) resulting from 
respiratory distress syndrome (n = 1) and pulmonary 
vascular disease (n = 1). The perioperative survival was 
92%. There were two late deaths due to infection (n = 1) 
and posttransplantation lymphoproliferative disease 
(n = 1) (Fig. 3). 
Other. Nine children less than 6 months of age with 
HLHS underwent cardiac transplantation and aortic 
reconstruction. One child was delivered by cesarian sec-
tion after the identification of a suitable organ donor at 35 
weeks' gestation. Fetal lung maturity was determined by 
amniocentesis. The child required mechanical ventilation 
and cardiac catheterization soon after delivery because of 
the association of total anomalous pulmonary venous 
return with HLHS. She was discharged to her home after 
a 12-week hospitalization but died of an influenza pneu-
monia shortly thereafter. HLHS was diagnosed in utero 
in two other children and they were listed, as fetuses, for 
cardiac transplantation; both patients underwent trans-
plantation after normal vaginal delivery. One of these 
children had an interrupted right-sided aortic arch in 
association with HLHS. The overall survival in this neo-
natal group was 66%. 
Seven children had unusual cardiomyopathies: myo-
carditis (n = 2), doxorubicin toxicity (n = 2), ischemic 
(n = I), valvular (n = 1), and cardiac angiosarcoma 
(n = 1). The peri operative survival in this heterogeneous 
group was 86%, however, two late deaths resulting from 
recurrent tumor (cardiac angiosarcoma at 10 months) 
and (gastrointestinal bleeding in a patient with human 
immunodeficiency virus and hemophilia) led to an over-
all survival of 57%. 
Mechanical circulatory support. Nine children (age 
range 4 to 14 years) required mechanical circulatory 
support before transplantation because of postcardiotomy 
pump failure (n = 4) and cardiomyopathy or myocardi-
tis (n = 5). Eight children were supported with ECMO 
for 3 to 8 days in the intensive care unit before transplan-
tation. Three of these children are of particular interest: 
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Fig. 3. Pediatric heart transplantation patient survival in pediatric heart transplantation on FK 506 immunosup-
pression. n = 26. Brookmeyer-Crowley 95% confidence interval for median survival time is not calculable. L VEF, Left 
ventricular ejection fraction. 
One 5-year-old child with myocarditis was supported by 
ECMO after cardiac arrest and 90 minutes of cardiopul-
monary resuscitation. His post-shock state was compli-
cated by coma, anuric renal failure, and hepatic insuffi-
ciency. He was supported by ECMO for 72 hours before 
cardiac transplantation. In addition, he required 3 days of 
ECMO support after transplantation because of respira-
tory distress syndrome. This child is doing well, 1 year 
after transplantation, and has normal neurologic, renal, 
and hepatic function. Two other children supported by 
ECMO required percutaneous transatrial septostomy to 
decompress the left atrium and relieve pulmonary vascu-
lar congestion (Fig. 3). The ninth child, who had idio-
pathic dilated cardiomyopathy, was 14 years of age and 
was supported with a N ovacor LV AS in conjunction with 
a centrifugal right ventricular assist system (RVAS). 
Three days after implantation, the RVAS was removed 
and the patient was eventually transferred to an out-of-
hospital, philanthropic, "Family House" setting approved 
by the Food and Drug Administration. During this 
patient's 4-month wait for transplantation he required 
mantle radiation treatment for occult stage I nodular 
sclerosing Hodgkin's disease, diagnosed at the time of 
L VAS implantation. This patient is disease free and doing 
well 2 years after transplantation. The perioperative sur-
vival in this mechanical circulatory support group was 
78%; however, two late deaths caused by respiratory dis-
tress syndrome (n = 1) and posttransplantation lym-
phoproliferative disease (n = 1) contributed to an overall 
survival of 56% in this group. The perioperative survival 
in patients receiving mechanical circulatory support in the 
early period (before July 1988) was 33% (1/3) compared 
with 100% in the late period (after June 1988). There was 
one late death during each period, such that the overall 
survival after mechanical circulatory support and trans-
plantation was 0% versus 83% in the early ami late peri-
ods, respectively. 
ECMO has been used in seven patients as posttrans-
plantation support (respiratory distress syndrome in three 
and posttransplantation lymphoproliferative disease in 
four); however, only the one patient noted earlier sur-
vived. A centrifugal R V AS was used for posttransplan-
tation right ventricular support in an 18-year-old boy with 
tetralogy of Fallot. This young man had four prior 
thoracic procedures, which included a right Blalock-
Taussig shunt, a Waterston shunt, a Potts shunt, and a 
Rastelli procedure. In addition, the patient had intra-
parenchymal pulmonary artery hypoplasia. The R VAS 
was able to be weaned and removed after 8 days. Over a 
period of 90 days the allograft right ventricular end-dias-
tolic pressure declined from 20 to 8 mm Hg and the 
patient was discharged to his home. 
Rejection. In patients who survived more than 30 days, 
there were 6 deaths (20%) resulting from rejection in 30 
patients treated with cyclosporine (mean follow-up 1300 
days) and no deaths resulting from rejection in 24 patients 
treated with FK 506 (mean follow-up 455 days) 
(p < 0.02, Fisher's). Two patients treated with cyclospo-
rine-based immunosuppression required a second trans-
plant operation (7 months and 7 years) for chronic rejec-
tion. The patient operated on at 7 months died 3 months 
later of persistent rejection. The patient operated on at 7 
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Fig. 4. Actuarial freedom from rejection in pediatric cardiac transplantation FK 506 immunosuppression compared 
to the cyclosporine (CyA) immunosuppression era. 
years had persistent rejection, which was reversed with 
conversion to FK 506; however, she died of suicide 1 V2 
years later. 
The actuarial freedom from rejection (grade 3A or 
greater) in the 24 children treated with FK 506 who 
survived more than 30 days was 60% at 3 and 6 months 
after transplantation. In the 15 children undergoing 
transplantation before November 1989 (survival >30 
days) treated with cyclosporine-based triple-drug immu-
nosuppression and rabbit antithymocyte globulin immu-
noprophylaxis (n = 5/15), the actuarial freedoms from 
rejection (grade 3A or greater) were 20% and 12% at 3 
and 6 months after transplantation, respectively 
(p < 0.001, Mantel-Cox and Breslow) (Fig. 4). In addi-
tion, 85% of the children treated with FK 506 were 
weaned off steroids, whereas all 15 patients treated with 
cyclosporine-based therapy continued to require steroid 
therapy, based on their rejection history. There were 0.9 
episodes of rejection per patient in the FK 506 group; 13 
ofthese 21 episodes occurred in 3 sensitized patients. Two 
patients in the FK 506 group required the addition of 
azathioprine and 1 patient was treated with OKT3. 
Eight patients whose initial immunosuppression was 
cyclosporine-based therapy were switched to FK 506 for 
persistent grade 2, 3A, or 3B rejection. Other complica-
tions that prompted FK 506 conversion were the inability 
to wean steroids (n = 8), hypertension (n = 6), hyperlip-
idemia (n = 4), and graft dysfunction (n = 1). These 
"rescue" patients tolerated the switch from cyclosporine 
to FK 506 without significant complications. Cyclospor-
ine was discontinued 24 to 48 hours before FK 506 
induction. No loading dose of FK 506 was administered. 
The patients were begun on oral FK 506,0.3 mg/kg per 
day, in two divided doses. Azathioprine was discontinued 
and steroids were given at half the maintenance dose. 
Pending improvement in subsequent biopsy results, ste-
roids were tapered. Four patients were tapered off pred-
nisone and four patients have been weaned to one quar-
ter of their maintenance dose. All patients have either had 
resolution of their rejection or have significant improve-
ment in the histologic endomyocardial biopsy grading of 
rejection; the one patient with graft dysfunction had res-
toration of normal hemodynamics. There was one death, 
caused by suicide, in the "rescue" group. 
Infection. There were 5 (7%) deaths caused by infec-
tion in the 66 children; two of these deaths occurred in the 
FK 506 group. A review of infectious complications in 
pediatric heart transplant recipients at Children's Hospi-
tal of Pittsburgh from 1982 to 1987 has been previously 
reportedJ Since November 1989, in the FK 506 study, 
there were 14 major infections in 10 patients. Seven 
(50%) major infections occurred in 2 neonates who 
required prolonged stays in the intensive care unit. One 
other patient, who required transplantation for tricuspid 
atresia and prior Fontan procedure, had three major 
infections and died of an infection. There were 15 minor 
infections in 10 patients. The most common (3/10) minor 
infection was varicella. 
Cardiac function. All surviving patients have excellent 
cardiac function. The average left ventricular ejection 
fraction measured by gated nuclear scan and/or echo-
cardiography was 66%. The range of left ventricular 
ejection fractions was 60% to 75% at the time of longest 
follow-up. The first annual coronary angiograms have 
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been normal in all cardiac allograft recipients treated with 
FK 506. 
Renal function and hypertension. FK 506 was 
extremely well tolerated in the pediatric group of cardiac 
transplant recipients. The average pretransplantation 
serum creatinine concentration was 0.7 ng/dl (standard 
error 0.1) and 3 months after transplantation it was 0.9 
ng/dl (standard error 0.1). Moderate oliguria and tran-
sient azotemia was associated with the intravenous 
administration of FK 506 particularly if preexisting renal 
dysfunction was present. Two patients required tempo-
rary peritoneal dialysis; one patient had renal vein throm-
bosis as a result of intravenous catheters and the other 
patient was in anuric renal failure before transplantation 
as a result of cardiac arrest. Normal renal function has 
returned in both of these patients. 
Only two patients have req uired antihypertensive ther-
apy. One patient who was treated for hypertension before 
transplantation continues to receive antihypertensive 
therapy. The other patient's blood pressure returned to 
normal after repair of an aortic coarctation. Compared 
with the prior cyclosporine era, in which the prevalence of 
hypertension was 70%, this represents a dramatic reduc-
tion in the necessity to treat hypertension in children after 
transplantation (p < 0.001, Fisher's). 
Metabolic studies and side effects. No pediatric 
patient receiving primary or rescue FK 506 immunother-
apy has required insulin therapy or had abnormal fasting 
blood sugar levels. Continued monitoring of hematologic 
and coagulation indexes, as well as of hepatic function, 
failed to reveal any abnormalities in our patients at this 
follow-up interval, with the exception of anemia. Anemia 
(hematocrit value <28%) has been problematic in 6 of the 
24 children (survival >30 days) treated with FK 506-
based immunosuppression. One of these children had a 
documented parvovirus infection, which caused her ane-
mia. The other 5 children have had normal anemia stud-
ies including bone marrow biopsies. This anemia is asso-
ciated with low erythropoietin levels and reticulocyte 
counts and has responded well to erythropoietin therapy. 
Further evaluation of the mechanism of this anemia is 
under study. Cholesterol and triglycerides have been 
slightly lower than those in cyclosporine-treated patients, 
but the difference was not statistically significant. Four 
patients had borderline elevation in uric acid levels. 
Moderately elevated serum potassium levels (K + > 5.5 
mEq/L) have also been observed in some patients, inde-
pendent of renal dysfunction, and we have avoided the 
exogenous administration of potassium in this group 
unless specifically indicated (serum K+ < 3.5 mEq/L). 
Side effects have been rare despite routine question-
naires during hospitalization and during outpatient fol-
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low-up. There have been no cases of seizure, cerebrovas-
cular accident, or neuropathy as a result of FK 506. One 
patient in the primary FK 506 therapy group had an 
intracerebral hemorrhage and seizure because of prior 
cerebral vasculitis caused by endocarditis. She recovered 
with minimal residual neurologic deficit. There have been 
occasional reports of extremity paresthesia, temperature 
malsensations in the hands and feet, and tremor, usually 
associated with elevated FK 506 levels. Muscle aches and 
mild insomnia were also reported rarely. Notably absent 
in this patient group were complaints of gingival hyper-
plasia, hirsutism, or abnormalities in facial bone growth 
previously observed in patients treated with cyclosporine. 
Posttransplantation lymphoproliferative disease. 
Five of 54 patients (9.2%) who survived more than 30 
days have posttransplantation lymphoproliferative dis-
ease. This disease developed early ( < I year) in 3 patients, 
at 4,4 and 6 months, and late (> 1 year), in 2 patients, at 
14 and 18 months. Four of these patients were treated 
with cyclosporine-based therapy, 1 of whom underwent 
FK 506 switch after 3 episodes of treated rejection. One 
patient was treated primarily with FK 506 immunosup-
pression. Three patients had associated infections at the 
time of presentation with disseminated posttransplanta-
tion lymphoproliferative disease, and they died. Two 
patients had localized disease in the form of multiple pul-
monary nodules and responded favorably to reduction in 
immunotherapy. Four of these 5 (80%) patients had an 
Ebstein-Barr infection associated with the development of 
posttransplantation lymphoproliferative disease. In our 
previously reported experience during 10 years of cyclo-
sporine-based immunosuppression in heart and lung 
transplantation, 14 of 486 (2.8%) adult cardiac recipients 
who survived more than 30 days had posttransplantation 
lymphoproliferative disease. Thus children with a cardi-
ac allograft are at significantly greater risk for the devel-
opment of posttransplantation lymphoproliferative dis-
ease (p < 0.02, x2) than their adult counterparts. The 
mortality from posttransplantation lymphoproliferative 
disease in both groups, however, was approximately 60%. 
Discussion 
Our early experience in pediatric heart transplantation 
was sobering. This was due to an exceedingly high peri-
operative mortality (60%) in children with congenital 
heart disease and a high late mortality (66%) in children 
with cardiomyopathy, primarily caused by rejection. In 
addition, children who required ECMO for pretransplan-
tation support also had an extremely high perioperative 
mortality (66%). Since July 1988, 34 children have 
undergone heart transplantation, and the data from this 
more recent series are encouraging. In the 11 patients 
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Fig. 5. Survival in pediatric heart transplantation cardiomyopathy and congenital heart disease (HD). Confidence 
interval is not calculable. 
with congenital heart disease undergoing transplantation 
since July 1988, the perioperative mortality was 0%. We 
attribute the marked improvement in perioperative sur-
vival in our patients with congenital heart disease to 
improved myocardial protection, surgical experience, and 
aggressive posttransplantation care. The difference in late 
mortality, 66% versus 7%, in the groups with early and 
late cardiomyopathy, respectively, was due to a signifi-
cant reduction in mortality from rejection. Reduced 
mortality from rejection (p < 0.02) and an increased 
freedom from rejection (p < 0.001) have occurred due, in 
part, to our increased experience with immunosuppres-
sion and in the diagnosis and treatment of rejection, as 
well as to the advent of FK 506, which has a substantial 
immune advantage in the child. 
Our experience with mechanical circulatory support in 
the child has also improved substantially since mid-1988. 
EeMO and Novacor LV AS have successfully bridged six 
children to transplantation. The perioperative survival in 
these 6 patients was 83%. Despite this encouraging trend 
in survival after cardiac transplantation in patients 
requiring pretransplantation mechanical circulatory sup-
port, a glaring deficiency in the armamentarium of the 
pediatric cardiac transplant surgeon is an efficient minia-
turized ventricular assist device. Ideally, in the near 
future, this type of technology will be available and will 
further improve our ability to support children for safer 
and longer periods. 
Two patients are worth special note with regard to their 
pretransplantation disease. One patient underwent suc-
cessful heart transplantation for a cardiac angiosarcoma. 
This child unfortunately had epicardial spread of his 
tumor at the time of the operation and died 10 months 
after transplantation. A recently published report on car-
diac angiosarcoma8 failed to consider the potential of 
heart transplantation as a treatment for this rare but 
lethal disorder. We believe that aggressive application of 
cardiectomy and transplantation, coupled with chemo-
therapy, could potentially produce results similar to 
treatments for other sarcomas. The other pretransplan-
tation disease which represents an increasing pool 'of 
pediatric heart transplantation candidates is the "end-
stage" Fontan. Infection, however, was the cause of mor-
tality in 1 of 2 F ontan patients in our series and produced 
substantial morbidity in the other. These patients have 
chronic venous hypertension and frequently have protein-
losing enteropathies, hypoalbuminemia, diminished cel-
lular and humoral immunity, malnutrition, and pleural, 
pericardial, and peritoneal effusions. Their posttransplan-
tation care will, of necessity, require reduced immuno-
suppression and aggressive diagnosis and treatment of 
infection. 
The trial of FK 506 immunosuppression in the adult 
cardiac transplant recipients has been successfu1.9 How-
ever, the salutary effects of this potent immunosuppres-
sive macrolide are far more dramatic in children. FK 506 
has become essentially the only immunosuppressive agent 
required for children after heart transplantation. It has 
obviated the need for steroids, nonspecific bone marrow 
suppressants, and antilymphocyte agents in the majority 
of pediatric recipients. Posttransplantation hypertension 
necessitating antihypertensive treatment has been virtu-
ally eliminated (p < 0.001). Renal toxicity in children 
treated with FK 506 has been mild. The tremendously 
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debilitating side effects for children of hirsutism, gingival 
hyperplasia, and abnormal facial bone growth observed 
with cyclosporine have not been seen in patients treated 
with FK 506. Not only can children with cardiac 
allografts now compete favorably with their peers in 
terms of activity, but their outward appearance will no 
longer betray their difference inside. The ability of FK 
506 to treat rejection and permit steroid withdrawal in 
patients unresponsive to conventional treatment is further 
testament to the potency and selectivity of this new agent. 
Our more recent experience in pediatric heart trans-
plantation would thus suggest that children with cardio-
myopathy and congenital heart disease can anticipate 
80% to 90% survival at the first year after transplantation 
(Fig. 5). In addition, high-risk children and those with 
cardiomyopathy of unusual cause can also benefit from 
the procedure, albeit at increased risk. Antenatal diagno-
sis of cardiac anomalies brings the fetus, as well, to the 
care of the pediatric cardiac transplant surgeon and chal-
lenges all of us to ensure ethical and equitable distribution 
of pediatric hearts for children. 
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Discussion 
Dr. Florentino Vargas (Buenos Aires, Argentina). I would 
like to share our initial experience at Italian Hospital of Buenos 
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Aires with pediatric heart transplantation. We started our 
pediatric experience 2 years ago, after a 3-year period of prep-
aration of the group and in the face of considerable environ-
mental and logistic difficulties. 
Since May 1990 nine children have undergone heart trans-
plantation, the smallest one weighing 5 kg. Because of the scar-
city of donors in Argentina, we accepted a considerable degree 
of donor-recipient mismatch in weight. In one extreme case the 
mismatch was 500%. In three recipients we accepted pulmonary 
vascular resistances higher than 5 units/m2. Crystalloid myo-
cardial protection was used at the donor's hospital and a dose of 
blood cardioplegic solution was added at our hospital in cases of 
distant procurement. 
There has been neither hospital nor long-term mortality so far 
for the group. The average hospital stay was 20 days and the 
average follow-up, 16 months. Rejection surveillance was done 
by noninvasive means. Three rejections occurred during the 
hospital stay and the remaining within the first year. All patients 
are doing well, in functional class I, and have returned to their 
normal activities. Patients of school age resumed unrestricted 
school activities, and two have returned to their own environ-
ment to help their families with farm work. The latter is an 
aspect that must be taken into account when planning the fol-
low-up, because our transplant recipients cannot be removed 
from the reality of Argentinean life. 
Ours is a triple-drug protocol, and we try to use the lowest 
dosage we can after the first year. In our series the percentage 
of hypertensive, cyclosporine-treated patients was similar to the 
percentage that you have described. Their hypertension seems 
to be well controlled with vasodilators. However, continuous 
Holter pressure monitoring disclosed that 60% of them became 
significantly hypertensive at night while sleeping. 
Although this phenomena has been reported after transplan-
tation in adults, we have no references in pediatric heart trans-
plant recipients. We managed this hypertension by reschedul-
ing the time when the patients received the vasodilators each 
day. Have you noted this problem in your cyclosporine-treated 
patients and have you any comment about it? 
Dr. Leonard L. Bailey (Loma Linda, Calif). The report 
represents a maturation in the Pittsburgh pediatric heart trans-
plant program. A host of variables, including surgical experi-
ence, improved technology, patient selection, and posttransplan-
tation immunomodulation have combined to produce the 
markedly improved early and intermediate survival of infants 
and children undergoing transplantation at Children's Hospital 
of Pittsburgh. 
The authors describe a number of potential advantages to the 
use of FK 506 as compared with their previous experience using 
cyclosporine-based triple-drug therapy. With so many variables 
affecting transplantation outcome in the more recent experi-
ence, I found it difficult to be sure how much of the improvement 
was due to FK 506 and how much was due to all these other 
factors. To really discover the potential advantages of FK 506, 
the authors, I believe, must conduct a prospective randomized 
study that would help eliminate many of these other variables. 
Perhaps a more valid measure of the benefits of FK 506 would 
be to compare recent Pittsburgh outcomes with those of anoth-
er center with comparable outcomes in which a different 
immunosuppressive regimen was used. For instance, combined 
early and late mortality from rejection in the cyclosporine-
treated group of infants in the Lorna Linda University series was 
6%, slightly less than the late rejection mortality of 7% attrib-
uted to the FK 506 group that you presented. 
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Another shortfall amid the fundamentally good news in this 
report from Pittsburgh is the fact that no statistical comparison 
was made between the cyclosporine and FK 506 groups with 
regard to early and late renal function. You showed us only how 
it turned out for the FK 506 group. It would be nice to have a 
comparison of the two groups on that issue too, since it is an 
issue. In addition, the assertion that FK 506 is steroid-sparing 
maintenance therapy is more a matter of opinion, at present, 
than a clearly defined fact. Our experience and that of the 
Harefield group suggest that chronic steroid use is not essential 
in cyclosporine-treated patients. 
I have two questions for you. First, are you involved in a pro-
spective randomized trial of FK 506 at Pittsburgh? Unot, why 
not? Second, have you observed an increase in infectious com-
plications among those patients treated with FK 506? I ask this 
because of our experience of an increased prevalence of lethal 
infections among juvenile primate recipients receiving FK 506 
in the laboratory. We are all eager to have an alternative semis-
elective immunosuppressant available for managing infants and 
children, and FK 506 is an exciting prospect. It remains to be 
seen if it is truly an improved agent, however. 
Dr. Griffith. First of all, Dr. Vargas, the benefits of the Gra-
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ham Traveling Fellowship have been quite obvious with your 
emerging, excellent series. Early on in the cyclosporine experi-
ence there were a number of publications from many centers, 
ours included, suggesting that hypertension was related to pos-
tural changes and loss of reflex control. 
Dr. Bailey, I appreciate your critical review of our manu-
script, to date the intent of our program's use of FK 506 was not 
as a comparison to cyclosporine. To randomize FK 506 in chil-
dren at Pittsburgh would span a decade during which the first 
treated patients clearly would not be representative of later 
recipients. I would like to see FK 506 introduced to other cen-
ters so that a more global representation of what it can do would 
be possible. At present the drug has been randomized in our 
adult lung population, which is at least a step in the right direc-
tion. 
We have no explanation for your cyclosporine rejection rate 
being less than ours. Perhaps you have a younger group of 
patients or render less tissue for examination. We believe that 
FK 506, as has been shown in our adult population in hearts, has 
resulted in fewer episodes of treated rejection. Other advan-
tages include reduced hypertension and a lack of facial brutal-
ization. 
